CBO reaffirms our innovation ecosystem leads to improved lives, long-term savings

The Congressional Budget Office (CBO) recentlyreleased a new report looking at trends in spending, prices and use of prescription drugs. While some politicians are trying to use the report to justify a flawed policy that would let the federal government set the price of medicines, a closer, less partisan look at CBO ’s findings reaffirms that the biopharmaceutical lifecycle is working exactly as intended.Even with the introduction of many new treatments and cures, theCBO found that the average net price per prescription fell from $57 in 2009 to $50 in 2018 in the Medicare Part D program and from $63 to $48 in the Medicaid program.Here are a few key points to keep in mind when reviewing the report:
Source: The Catalyst - Category: Pharmaceuticals Authors: Tags: Drug Cost Health Insurance Proactive Agenda Source Type: news